华润三九（000999）披露公司产品通过谈判首次纳入国家医保目录，12月08日股价下跌0.49%

Core Viewpoint - China Resources Sanjiu (华润三九) has successfully negotiated to include its product Yiqi Qingfei Granules in the National Medical Insurance Directory, which is expected to enhance its product portfolio in the respiratory field, although it is not anticipated to have a significant short-term impact on the company's financial performance [1]. Group 1: Company Performance - As of December 8, 2025, China Resources Sanjiu's stock closed at 28.15 yuan, down 0.49% from the previous trading day, with a total market capitalization of 46.848 billion yuan [1]. - The stock opened at 28.3 yuan, reached a high of 28.39 yuan, and a low of 28.1 yuan, with a trading volume of 2.25 billion yuan and a turnover rate of 0.48% [1]. Group 2: Product Development - Yiqi Qingfei Granules, classified as a traditional Chinese medicine (Category 3.2), is indicated for short-term symptoms following epidemics related to Qi and Yin deficiency, spleen deficiency, and residual pathogenic factors [1]. - The product was approved for market launch in January 2025 and is currently undergoing post-market academic promotion and online sales [1]. - Inclusion in the National Medical Insurance Directory will take effect from January 1, 2026, with the agreement valid until December 31, 2027 [1].